|
[1]
|
Zhu, X. and Wu, W. (2025) Bidirectional Mendelian Randomization Identifies Plasma Proteins Associated with Urticaria Risk. Archives of Dermatological Research, 317, Article No. 430. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Muñoz, M., Kocatürk, E., Maurer, M. and Kolkhir, P. (2024) Emerging Therapeutics in Chronic Urticaria. Immunology and Allergy Clinics of North America, 44, 517-528. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Zuberbier, T., Ensina, L.F., Giménez-Arnau, A., Grattan, C., Kocatürk, E., Kulthanan, K., et al. (2024) Chronic Urticaria: Unmet Needs, Emerging Drugs, and New Perspectives on Personalised Treatment. The Lancet, 404, 393-404. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Smola, A., Hawerkamp, H.C., Oláh, P., Kislat, A., Duschner, N., Homey, B., et al. (2025) Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation. Immunity, Inflammation and Disease, 13, e70132. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Kolkhir, P., Bonnekoh, H., Metz, M. and Maurer, M. (2024) Chronic Spontaneous Urticaria. JAMA, 332, 1464-1477. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kocatepe, G., Kaya, M.A., Bingol, A. and Uygun, D.F.K. (2024) Is It Possible to Use Inflammatory Markers as Potential Biomarkers for Chronic Urticaria? Pediatric Allergy, Immunology, and Pulmonology, 37, 47-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Bernstein, J.S., Bernstein, J.A. and Lang, D.M. (2024) Chronic Spontaneous Urticaria. Immunology and Allergy Clinics of North America, 44, 595-613. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Podder, I., Dhabal, A. and Chakraborty, S.S. (2023) Efficacy and Safety of Up-Dosed Second-Generation Antihistamines in Uncontrolled Chronic Spontaneous Urticaria: A Review. The Journal of Clinical and Aesthetic Dermatology, 16, 44-50.
|
|
[9]
|
Abdul-Reda, F. and AH Jabarah AL-Zobaidy, M. (2024) Evaluation of Bilastine’s Efficacy and Safety in Treating Chronic Idiopathic Urticaria in Iraqi Patients. Medical Journal of The Islamic Republic of Iran, 38, Article 121. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Shah, B., Dhoot, D., Choudhary, A., Jangid, N., Mistry, D., Shah, S., et al. (2022) A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria. Clinical, Cosmetic and Investigational Dermatology, 15, 261-270. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Ansotegui, I.J., Bernstein, J.A., Canonica, G.W., Gonzalez-Diaz, S.N., Martin, B.L., Morais-Almeida, M., et al. (2022) Insights into Urticaria in Pediatric and Adult Populations and Its Management with Fexofenadine Hydrochloride. Allergy, Asthma & Clinical Immunology, 18, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Cho, Y., Chan, T.C., Lee, C., Chou, W., Hsiao, P., Chen, Y., et al. (2022) Journal of the Formosan Medical Association, 121, 1191-1203. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kalkan, F., Yeşillik, S., Demirel, F., Sönmez, E., Balaban, Y., İnan, M.İ., et al. (2025) Comparison of Long Term Efficacy and Cost-Effectiveness of Omalizumab in 150 Mg and 300 Mg Doses in Patients with Chronic Spontaneous Urticaria. Anais Brasileiros de Dermatologia, 100, 31-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
López, C., Depreux, N., Bielsa, I., Roger, A., Quirant-Sanchez, B., Basagaña, M., et al. (2024) Peripheral Blood T-Cell Modulation by Omalizumab in Chronic Urticaria Patients. Frontiers in Immunology, 15, Article 1413233. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Khan, M.S., Nadeem, Y., Bilal, M.M., Baloch, A., Rasheed, M., Jehandad, H., et al. (2025) From Wheal to Wellness: Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. Archives of Dermatological Research, 317, Article No. 503. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
McLaren, J., Chon, Y., Gorski, K.S., Bernstein, J.A., Corren, J., Hayama, K., et al. (2025) Tezepelumab for the Treatment of Chronic Spontaneous Urticaria: Results of the Phase 2b INCEPTION Study. Journal of Allergy and Clinical Immunology, 155, 1945-1956. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Tuncay, G., Damadoglu, E., Karakaya, G. and Fuat Kalyoncu, A. (2025) Comparison of the Characteristics of Patients with Chronic Urticaria Receiving Standard-or High-Dose Omalizumab. European Annals of Allergy and Clinical Immunology. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Maloney, N.J., Tegtmeyer, K., Zhao, J., et al. (209) Dupilumab in Dermatology: Potential for Uses beyond Atopic Dermatitis. Journal of Drugs in Dermatology, 18, 1053-1055.
|
|
[19]
|
Lee, J.K. and Simpson, R.S. (2019) Dupilumab as a Novel Therapy for Difficult to Treat Chronic Spontaneous Urticaria. The Journal of Allergy and Clinical Immunology: In Practice, 7, 1659-1661.e1. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Abadeh, A. and Lee, J.K. (2022) Long-Term Follow-Up of Patients Treated with Dupilumab for Chronic Spontaneous Urticaria: A Case Report. SAGE Open Medical Case Reports, 10. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Chiarella, S.E. (2019) Immunobiologic Treatments for Severe Asthma, Atopic Dermatitis, and Chronic Urticaria. Allergy and Asthma Proceedings, 40, 485-489. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Pitlick, M.M. and Pongdee, T. (2022) Combining Biologics Targeting Eosinophils (IL-5/IL-5R), Ige, and IL-4/IL-13 in Allergic and Inflammatory Diseases. World Allergy Organization Journal, 15, Article ID: 100707. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Greiner, B., Nicks, S., Adame, M. and McCracken, J. (2022) Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review. Clinical Reviews in Allergy & Immunology, 63, 381-389. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Mubariki, R., Samara, R., Gimenez-Arnua, A.M., Maurer, M., Bejar, J., Toubi, E., et al. (2024) CD4+CCR5+ T Cells and CCL3+ Mast Cells Are Increased in the Skin of Patients with Chronic Spontaneous Urticaria. Frontiers in Immunology, 15, Article 1327040. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Ji, J., Tang, M., Zhao, Y., Zhang, C., Shen, Y., Zhou, B., et al. (2024) In Chronic Spontaneous Urticaria, Increased Galectin‐9 Expression on Basophils and Eosinophils Is Linked to High Disease Activity, Endotype‐Specific Markers, and Response to Omalizumab Treatment. Allergy, 79, 2435-2447. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Altrichter, S., Staubach, P., Pasha, M., Singh, B., Chang, A.T., Bernstein, J.A., et al. (2022) An Open-Label, Proof-Of-Concept Study of Lirentelimab for Antihistamine-Resistant Chronic Spontaneous and Inducible Urticaria. Journal of Allergy and Clinical Immunology, 149, 1683-1690.e7. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Leonardi, A. (2020) Treatment of Severe Allergic Conjunctivitis with AK002 Indicated Improvement of Ocular Signs and Symptoms and Reduction of Severity of Comorbid Atopic Diseases in a Phase 1b Open-Label Study. European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting 2020.
|
|
[28]
|
Siebenhaar, F., Altrichter, S., Bonnekoh, H., Hawro, T., Hawro, M., Michaelis, E.G., et al. (2023) Safety and Efficacy of Lirentelimab in Patients with Refractory Indolent Systemic Mastocytosis: A First-In-Human Clinical Trial. British Journal of Dermatology, 189, 511-519. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Maurer, M., Kolkhir, P., Pereira, M.P., Siebenhaar, F., Witte‐Händel, E., Bergmann, K., et al. (2024) Disease Modification in Chronic Spontaneous Urticaria. Allergy, 79, 2396-2413. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Metz, M., Giménez-Arnau, A., Hide, M., Lebwohl, M., Mosnaim, G., Saini, S., et al. (2025) Remibrutinib in Chronic Spontaneous Urticaria. New England Journal of Medicine, 392, 984-994. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
LaCava, A.F. and Fadugba, O.O. (2023) Cyclosporine for Omalizumab-Refractory Chronic Urticaria: A Report of Five Cases. Allergy, Asthma & Clinical Immunology, 19, Article No. 78. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Bei, W., Qian, J., Zilu, Q., Kai, C., Ruili, J., Feng, H., et al. (2023) Comparing Four Immunosuppressive Agents for Chronic Spontaneous Urticaria-A Network Meta-Analysis. International Immunopharmacology, 123, Article ID: 110577. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Natarajan, S. and Subramanian, P. (2022) Open-label Non-Blinded Cohort Study on Anti-Histaminic Resistant Chronic Idiopathic Urticaria in Western India. Indian Journal of Dermatology, 67, 518-523. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Morioke, S., Moriwaki, M., Tanaka, A. and Hide, M. (2024) A Case of Chronic Spontaneous Urticaria with Wheals Lasting for More than a Week. The Journal of Dermatology, 52, 344-347. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Mansouri, P., Mozafari, N., Chalangari, R. and Martits‐Chalangari, K. (2022) Efficacy of Oral Tofacitinib in Refractory Chronic Spontaneous Urticaria and Urticarial Vasculitis. Dermatologic Therapy, 35, e15932. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
De, A., Pal, S., Singh, S., Chakroborty, D. and Godse, K. (2024) An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria. Indian Journal of Dermatology, 69, 312-316. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Du, N., Wang, D., Yang, J., Zhang, Y., Lyu, X., Min, W., et al. (2024) Case Report: Exploration of Abrocitinib in the Treatment of Refractory Chronic Spontaneous Urticaria: A Case Series. Frontiers in Immunology, 15, Article 1466058. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Yao, Y., Ravn Jørgensen, A. and Thomsen, S.F. (2019) Biologics for Chronic Inflammatory Skin Diseases: An Update for the Clinician. Journal of Dermatological Treatment, 31, 108-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
U.S. Food and Drug Administration (2022) Drug Safety Oversight Board (DSOB) Meeting March 15, 2022: Public Summary. FDA.
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board-dsob-meeting-march-15-2022
|
|
[40]
|
Du, Y. (2024) Efficacy Evaluation of Acupuncture Combined with Pricking Blood Therapy in the Treatment of Chronic Spontaneous Urticaria: A Randomized Controlled Trial. American Journal of Translational Research, 16, 5268-5282. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Hızlı, P., Gülcen, B. and Kılıç, F.A. (2024) Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omalizumab: A Study of 61 Cases. Medical Science Monitor, 30, e945935. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Ting Pao Lin, I., Ghazali, N.I., Teo, Y., Lai, S.L., Bakhtiar, M.F. and Tang, M.M. (2024) Autologous Serum Therapy in Recalcitrant Chronic Spontaneous Urticaria: Experience from Three Dermatology Clinics in Malaysia. Indian Journal of Dermatology, 69, 406-410. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Shirazi, M.T., Goodarzi, A., Ghobadi, A. and Eghbalian, F. (2024) Jujube Oxymel for the Treatment of Chronic Spontaneous Urticaria: Efficacy and Safety. Advanced Biomedical Research, 13, 91. [Google Scholar] [CrossRef] [PubMed]
|